Výsledky vyhledávání - "Touchette DR"

Akademický článek

Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study [Corrigendum]

Autor: Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, Patel S, Edwards D, Touchette DR, Portillo E, Feigler N, Pollack M

Publikováno v: International Journal of COPD, Vol Volume 19, Pp 1799-1800 (2024)

Strange C, Tkacz J, Schinkel J, et al. Int J Chron Obstruct Pulmon Dis. 2023;18:2245–2256. The authors have advised that there are errors in the 95% CI interval values on page 2248. Results, Baseline and Follow-Up Exacerbation Rates, sentence 3, th

Externí odkaz: https://doaj.org/article/7082906328ac4386acd9336cb2c0374b

Zobrazit plný text záznamu

Akademický článek

Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study

Autor: Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, Patel S, Edwards D, Touchette DR, Portillo E, Feigler N, Pollack M

Publikováno v: International Journal of COPD, Vol Volume 18, Pp 2245-2256 (2023)

Charlie Strange,1 Joseph Tkacz,2 Jill Schinkel,2 Benjamin Lewing,2 Barnabie Agatep,2 Sean Swisher,3 Sushma Patel,3 Devechio Edwards,3 Daniel R Touchette,4 Edward Portillo,5 Norbert Feigler,3 Michael Pollack3 1College of Medicine, The Medical Universi

Externí odkaz: https://doaj.org/article/3599284e7b0743a28b914af1896ed62e

Zobrazit plný text záznamu

Akademický článek

PRIMUS – Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation

Autor: Tkacz J, Evans KA, Touchette DR, Portillo E, Strange C, Staresinic A, Feigler N, Patel S, Pollack M

Publikováno v: International Journal of COPD, Vol Volume 17, Pp 329-342 (2022)

Joseph Tkacz,1 Kristin A Evans,1 Daniel R Touchette,2 Edward Portillo,3 Charlie Strange,4 Anthony Staresinic,5 Norbert Feigler,5 Sushma Patel,5 Michael Pollack5 1Life Sciences, IBM Watson Health, Cambridge, MA, USA; 2Center for Pharmacoepidemiology a

Externí odkaz: https://doaj.org/article/e9e1bd52a0844a6a8745a7e542aceabb

Zobrazit plný text záznamu

Akademický článek

Pilot assessment of patient satisfaction and clinical impact of Medicare Part D in diabetic geriatric patients

Autor: Kim SL, Touchette DR, Stubbings JA, Schullo-Feulner AM, Pater KS

Publikováno v: Pharmacy Practice, Vol 6, Iss 3, Pp 128-135 (2008)

Objectives: To assess patients’ 1) satisfaction with their decision to enroll or not enroll in the Medicare Part D program, and 2) clinical status of diabetes before and after decision to enroll in Medicare Part D.Methods: Patients 65 years or olde

Externí odkaz: https://doaj.org/article/df0dee202b774b1dab17cb041e4651d3

Zobrazit plný text záznamu

Akademický článek

Improving outpatient warfarin use for hospitalized patients with atrial fibrillation

Autor: Touchette DR,, McGuinness ME, Stoner S, Shute D, Edwards JM, Ketchum K

Publikováno v: Pharmacy Practice, Vol 6, Iss 1, Pp 43-50 (2008)

Atrial fibrillation affects an estimated 5 million Americans and accounts for approximately 15% of all strokes. Few studies have successfully addressed patient screening, assessment, and introduction of appropriate antithrombotic therapy in patients

Externí odkaz: https://doaj.org/article/fbde5bb4d1c74ba4902ee545d07dd3f9

Zobrazit plný text záznamu

Akademický článek

Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention

Autor: Patel V, Lin FJ, Ojo O, Rao S, Yu S, Zhan L, Touchette DR

Publikováno v: Pharmacy Practice, Vol 12, Iss 3, p 438 (2014)

Background: Prasugrel is recommended over clopidogrel in poor/intermediate CYP2C19 metabolizers with acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), reducing the risk of ischemic events. CYP2C19 genetic testing can

Externí odkaz: https://doaj.org/article/231204ff5ab241c88ef856125b53f637

Zobrazit plný text záznamu